Trial News & Events

Ultra-high dose methylcobalamin (E0302) prolongs survival of ALS

Report of 7 years’ randomised double-blind, phase 3 clinical trial The present study demonstrated for the first time that ultra-high dose methylcobalamin can significantly prolong survival and retard progression in ALS if administered early. Read the full abstract here.